Intravitreal injection (IVI) delivers pharmacologic agents directly into the vitreous cavity, producing high intraocular drug concentrations while minimizing systemic exposure. It is now the standard of care for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), myopic choroidal neovascularization (CNV), and other posterior-segment diseases. As the armamentarium of anti-vascular endothelial growth factor (anti-VEGF) and adjunctive agents continues to grow, worldwide IVI volumes are projected to increase further [
1,
2]. Although generally safe, IVI is not without risk. Reported procedure-related adverse events include subconjunctival hemorrhage, transient or sustained intraocular pressure elevation, uveitis, intraocular hemorrhage, retinal detachment, and infectious endophthalmitis [
3]. Beyond these potential risks, anti-VEGF IVIs often require repetitive treatments over several years for patients [
4,
5], making it crucial to reduce patient burden during the procedure. Consequently, optimizing the patient experience, particularly minimizing pain, has become an essential component of long-term treatment adherence.
The present retrospective crossover study was conducted to elucidate: (1) whether 40-gauge needles reduce patient-reported pain compared with conventional 30-gauge needles, and (2) how needle miniaturization influences immediate post-injection events—specifically subconjunctival hemorrhage, which may affect cosmetic satisfaction and comfort, and vitreous reflux, which could compromise delivered drug dose. By controlling inter-individual variability within the same patients, we aimed to provide a clearer understanding of the clinical trade-offs associated with adopting ultrathin needles for IVI.
Results
Forty-two patients received paired injections and were included in the analysis. The mean age was 69.3 ± 11.5 years, and 29 participants (69.0%) were male. Treatment indications comprised nAMD in 31 eyes (73.8%), DME in 3 (7.1%), RVO in 2 (4.8%), myopic CNV in 1 (2.4%), and other diagnoses in 5 (11.9%). Injected agents were aflibercept (47.6%), ranibizumab (33.3%), and bevacizumab (19.0%). Thirty-seven patients received two successive injections to the same eye 1 month apart, whereas five underwent bilateral injections on a single day; each patient thus served as their own control (
Table 1).
Across the cohort, VAS pain scores were significantly lower with ultrathin 40-gauge needles than with conventional 30-gauge needles (mean ± SD, 2.33 ± 1.26 vs. 4.02 ± 1.73; mean paired difference ± standard error, −1.69 ± 0.33;
t = 5.19; 95% confidence interval, −2.34 to −1.03;
p < 0.001). Vitreous reflux likewise decreased, with median grade falling from 2 (interquartile range [IQR], 2-3) after 30-gauge injections to 0 (IQR, 0-1) after 40-gauge injections (Wilcoxon signed-rank Z = −3.62;
p < 0.001). In contrast, subconjunctival hemorrhage showed no meaningful difference between gauges (median grade [IQR], 0 [0-1] for both;
p = 0.928) (
Table 2). No injection-related severe adverse events—such as endophthalmitis, retinal break, sustained intraocular pressure rise, or severe pain requiring additional anesthesia—were observed. Adverse events were assessed on the day following the injection, and subsequent follow-up confirmed the absence of any complications.
Discussion
This retrospective crossover study shows that substituting an ultrathin 40-gauge needle for the conventional 30-gauge device yields clinically relevant benefits during IVI. A two-thirds reduction in outer diameter produced a significant decrease in patient-reported pain and an even greater reduction in vitreous reflux, while the incidence of subconjunctival hemorrhage remained unchanged. Because anti-VEGF therapy frequently requires lifelong, repetitive dosing, any strategy that enhances comfort and preserves delivered dose has the potential to improve long-term adherence and visual outcomes.
Currently, the 30-gauge needle is the most used device for IVIs. Although prior work has suggested an association between needle diameter and pain perception, the evidence remains inconsistent [
11]. Aderman et al. [
12] and Eaton et al. [
13] compared 30-gauge with 33-gauge needles and found no statistically significant differences in pain scores between the two groups. By contrast, Sasajima et al. [
14] reported that patients experienced less pain with 34-gauge needles compared with 30-gauge, and a South Korean study similarly demonstrated lower pain scores with 40-gauge compared to 30-gauge needles [
15]. These conflicting findings are likely attributable to the relatively small caliber differences assessed in most prior studies. To address this limitation, the present study compared 30-gauge needles (outer diameter approximately 300 μm) with ultrathin 40-gauge needles (outer diameter approximately 100-120 μm), representing a substantially greater reduction in caliber (approximately 60%-67%). We further sought to objectively and reliably evaluate postprocedural pain using the VAS, a patient-friendly instrument that is particularly suited for elderly individuals who constitute a major proportion of this population [
16]. Using this approach, we demonstrate that the use of 40-gauge needles significantly reduced postinjection pain.
The observed pain reduction is clinically meaningful from the patient’s perspective. The minimal clinically important difference (MCID) for acute pain has been established as 1.4 to 1.8 points on a 10-point VAS or a relative reduction of at least 23.0% [
17,
18]. Our study demonstrated a 1.69-point decrease (from 4.02 to 2.33), corresponding to a 42.0% reduction from baseline. Both metrics exceed the established MCID thresholds, indicating that the pain reduction is clinically perceptible and meaningful to patients undergoing IVI.
Previous studies have suggested that demographic factors such as age and sex may influence pain perception during IVI, but their findings have been inconsistent. Rifkin and Schaal [
19] reported lower pain scores in female patients and in individuals aged ≥66 years, whereas Shin et al. [
20] observed higher pain scores in women and no significant association with age. In contrast, Damasceno et al. [
21] found no correlation between pain and either age or sex. Such discrepancies highlight the potential for demographic and inter-individual variability to confound the assessment of procedural discomfort. To minimize these effects, we adopted a within-subject crossover design in which each patient received both 30- and 40-gauge injections—either bilaterally on the same day or sequentially 1 month apart. The gauge order was alternated at the injector’s discretion. This approach reduced the influence of age-, sex-, and patient-specific factors, while also controlling for habituation, anxiety, and other effects inherent to repeated procedures. Through this design, we aimed to more clearly isolate the impact of needle gauge on pain perception.
Given the subjective nature of pain assessment and the methodological limitations of prior studies, our approach offers several advantages. First, by evaluating the same patients, we were able to minimize inter-individual variability in pain perception, which can be influenced by prior experiences, psychological state, and expectation effects [
22]. Second, by administering the same medication to each patient across injections, we eliminated potential confounding from drug-related differences. Previous studies have shown that bevacizumab is associated with higher pain scores compared to aflibercept or ranibizumab [
23], and that aflibercept causes more discomfort than ranibizumab [
24], likely due to compositional or pH-related factors. By controlling such variables, our design enabled a more direct evaluation of the influence of needle gauge on pain.
Subconjunctival hemorrhage, although cosmetically troubling for some patients, was not affected by needle caliber in our series. This result is consistent with evidence that systemic factors—hypertension, diabetes, and anticoagulant therapy—and transient periprocedural spikes in arterial pressure are the principal determinants of hemorrhagic risk, rather than the scleral tract diameter itself [
25,
26]. Accordingly, the transition to 40-gauge needles should not engender additional bleeding concerns in routine practice.
Vitreous reflux fell dramatically with 40-gauge needles, a finding with two important implications. First, because the intravitreal aliquot is small (approximately 0.05 mL), minimizing reflux helps ensure that the intended therapeutic dose reaches the posterior segment. Second, a smaller scleral tract may reduce the theoretical risk of pathogen ingress and subsequent endophthalmitis—the most feared complication of the procedure [
27]. Although no infections occurred in the present series, larger cohorts and extended follow-up are required to substantiate this potential safety advantage.
This study has several limitations that should be considered when interpreting the results. First, this was a retrospective study; however, the data were collected as part of a structured internal clinical practice evaluation conducted when the 40-gauge needle was introduced at our institution. Outcome measures were predefined, and all data—including pain scores, video documentation, and grading of subconjunctival hemorrhage and vitreous reflux—were recorded contemporaneously during routine clinical care, prior to the conception of the current analysis. These efforts were made to ensure the objectivity and completeness of the data, minimizing the risk of retrospective bias in data collection. Institutional review board approval was subsequently obtained after recognizing the scientific value of the systematically documented data. Second, the modest sample size and single-center design limit the generalizability of our findings and preclude assessment of long-term outcomes such as intraocular pressure fluctuations and late-onset adverse events. Third, although the inclusion of heterogeneous retinal diseases reflects real-world clinical practice, the limited subgroup sizes hinder comprehensive disease-specific analyses, which may introduce confounding. Fourth, drug histories, including anticoagulant use (which may also influence subconjunctival hemorrhage), were not systematically documented at each IVI time point, which we acknowledge as a limitation. However, given that injections were performed in the same patients either on the same day or at a 1-month interval, we believe there is little difference in systemic medication use between the groups (30-gauge vs. 40-gauge). This paired design enables within-subject comparisons that are independent of anticoagulant status. Fifth, because gauge order was alternated at the injector’s discretion rather than randomized, we cannot exclude order- or period-related effects (e.g., anxiety reduction with repeat procedures). Finally, our grading method based on maximal bleb diameter for vitreous reflux and subconjunctival hemorrhage, while practical and aligned with previous studies, may underestimate true reflux occurrence, especially when reflux occurs without bleb formation due to vitreous liquefaction.
Regarding 40-gauge needles, several clinical limitations are noteworthy. Their higher cost may increase patient burden. Due to their thin and delicate structure, 40-gauge needles can bend or deform during scleral penetration, complicating injections. Moreover, the small lumen may clog when injecting suspensions with larger particles such as triamcinolone. Nevertheless, the significant reduction in injection pain with 40-gauge needles represents an important clinical advantage, making them a valuable option despite these challenges.
In summary, ultrathin 40-gauge needles provide meaningful clinical benefits during IVIs by significantly reducing patient-reported pain and vitreous reflux without increasing subconjunctival hemorrhage. This simple modification enhances patient comfort and may improve drug delivery efficiency in managing chronic retinal diseases. Future multicenter studies with larger cohorts and longer follow-ups are needed to confirm these findings and further optimize clinical practice.